The first step to validate the deficit of TGF-β1 in DS in our study has been to employing an ex vivo approach, and we found that TGF-β1 concentrations are reduced in parallel both in the plasma and in the PBMCs of individuals with DS. This evidence concerns the gene TGFB1 and Dravet syndrome.